國立虎尾科技大學 |

Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine/ edited by Christophe Le Tourneau, Maud Kamal.
other author:	Le Tourneau, Christophe.
Published:	Cham :Springer International Publishing : : 2015.,
Description:	x, 144 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Clinical trials. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-22189-2
ISBN:	9783319221892

Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine
Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine[electronic resource] /edited by Christophe Le Tourneau, Maud Kamal. - Cham :Springer International Publishing :2015. - x, 144 p. :ill. (some col.), digital ;24 cm.

Introduction: Rationale for Precision Medicine Clinical Trials -- The Key Role of Pathology in the Context of Precision Medicine Trials -- Basis for Molecular Genetics in Cancer -- Microarrays Based Molecular Profiling to Identify Genomic Alterations -- High Throughput Technologies: DNA and RNA Sequencing Strategies and Potential -- Bioinformatics for Precision Medicine in Oncology -- Assessment of Biomarkers' Predictive Value of Efficacy -- Designs for Evaluating Precision Medicine Trials -- Conclusions and Perspectives: Challenges for the Clinical Implementation of Precision Medicine Trials.

This original book provides readers with an overview of the latest developments in personalized medicine clinical trials in oncology. The topics covered range from the rationale behind this new generation of clinical trials and the latest statistical models for high-throughput molecular techniques, bioinformatics, high-throughput screening molecular techniques and the challenges entailed by implementing them in daily practice. It also covers the key role of pathology in the validation of molecular results and the complex assessment of predictive biomarkers. The different topics covered are supplemented by unique concrete examples based on the SHIVA trial. The authors are all members of the French Curie Institute, one of the world's foremost cancer research institutions.

ISBN: 9783319221892

Standard No.: 10.1007/978-3-319-22189-2doiSubjects--Topical Terms:

581858
Clinical trials.

LC Class. No.: R853.C55

Dewey Class. No.: 616.027

Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine
LDR:02369nam a2200313 a 4500 001 837331
003 DE-He213
005 20160308102132.0
006 m d
007 cr nn 008maaau
008 160421s2015 gw s 0 eng d
020 $a 9783319221892 $q (electronic bk.)
020 $a 9783319221885 $q (paper)
024 7 $a 10.1007/978-3-319-22189-2 $2 doi
035 $a 978-3-319-22189-2
040 $a GP $c GP
041 0 $a eng
050 4 $a R853.C55
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.027 $2 23
090 $a R853.C55 $b P187 2015
245 0 0 $a Pan-cancer integrative molecular portrait towards a new paradigm in precision medicine $h [electronic resource] / $c edited by Christophe Le Tourneau, Maud Kamal.
260 $a Cham : $c 2015. $b Springer International Publishing : $b Imprint: Springer,
300 $a x, 144 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Introduction: Rationale for Precision Medicine Clinical Trials -- The Key Role of Pathology in the Context of Precision Medicine Trials -- Basis for Molecular Genetics in Cancer -- Microarrays Based Molecular Profiling to Identify Genomic Alterations -- High Throughput Technologies: DNA and RNA Sequencing Strategies and Potential -- Bioinformatics for Precision Medicine in Oncology -- Assessment of Biomarkers' Predictive Value of Efficacy -- Designs for Evaluating Precision Medicine Trials -- Conclusions and Perspectives: Challenges for the Clinical Implementation of Precision Medicine Trials.
520 $a This original book provides readers with an overview of the latest developments in personalized medicine clinical trials in oncology. The topics covered range from the rationale behind this new generation of clinical trials and the latest statistical models for high-throughput molecular techniques, bioinformatics, high-throughput screening molecular techniques and the challenges entailed by implementing them in daily practice. It also covers the key role of pathology in the validation of molecular results and the complex assessment of predictive biomarkers. The different topics covered are supplemented by unique concrete examples based on the SHIVA trial. The authors are all members of the French Curie Institute, one of the world's foremost cancer research institutions.
650 0 $a Clinical trials. $3 581858
650 0 $a Cancer $x Molecular aspects. $3 668357
650 0 $a Cancer $x Genetic aspects. $3 782504
650 1 4 $a Medicine& Public Health. $3 1068104
650 2 4 $a Oncology. $3 593951
650 2 4 $a Pathology. $3 668553
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Le Tourneau, Christophe. $3 1068102
700 1 $a Kamal, Maud. $3 1068103
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-22189-2
950 $a Medicine (Springer-11650)